Research ArticleSystemic Sclerosis
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin and Robert M. Elashoff
The Journal of Rheumatology October 2019, 46 (10) 1316-1325; DOI: https://doi.org/10.3899/jrheum.180441
Elizabeth R. Volkmann
From the Department of Medicine and Department of Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California; Department of Biomathematics, University of California, Los Angeles, California; Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan,
USA; Department of Rheumatology, Oslo University Hospital, Oslo,
Norway.
Donald P. Tashkin
Myung Sim
Ning Li
Dinesh Khanna
Michael D. Roth
Philip J. Clements
Anna-Maria Hoffmann-Vold
Daniel E. Furst
Grace Kim
Jonathan Goldin
Data supplements
Data Supplement
180441 Video Abstract
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 46, Issue 10
1 Oct 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin, Robert M. Elashoff
The Journal of Rheumatology Oct 2019, 46 (10) 1316-1325; DOI: 10.3899/jrheum.180441
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip J. Clements, Anna-Maria Hoffmann-Vold, Daniel E. Furst, Grace Kim, Jonathan Goldin, Robert M. Elashoff
The Journal of Rheumatology Oct 2019, 46 (10) 1316-1325; DOI: 10.3899/jrheum.180441